Comparative Pharmacology
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus SODIUM CHROMATE CR 51.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDEOXYGLUCOSE F18 versus SODIUM CHROMATE CR 51.
FLUDEOXYGLUCOSE F18 vs SODIUM CHROMATE CR 51
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludeoxyglucose F18 is a glucose analog that is taken up by cells via glucose transporters (GLUT), particularly GLUT-1. It is phosphorylated to FDG-6-phosphate by hexokinase, which cannot be further metabolized, leading to intracellular accumulation proportional to glucose metabolism. It emits positrons detected by PET imaging.
Radiolabeled sodium chromate (51Cr) binds to red blood cells, tagging them for survival studies. 51Cr emits gamma radiation, allowing detection and quantification of RBC mass and survival via scintillation counting or imaging.
5-10 mCi (185-370 MBq) intravenous injection, single dose for PET imaging.
Intravenous injection, 5-30 microcuries (0.185-1.11 MBq) as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 110 minutes (range 100–120 minutes). This reflects clearance of unmetabolized FDG from plasma and is clinically relevant for imaging timing, as optimal image acquisition occurs 30–60 minutes post-injection to allow for target-to-background ratio maximization.
The biological half-life is approximately 27–30 days. Clinically, gradual clearance from blood and tissues occurs over weeks to months.
Primarily renal; approximately 90% of injected activity is excreted unchanged in urine within the first 2 hours post-injection. Less than 5% is eliminated via feces.
Primarily renal. Approximately 90% of absorbed dose is excreted in urine within 48 hours. Fecal excretion accounts for less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical